Differentiation between Good and Low-Responders to Intravitreal Ranibizumab for Macular Edema Secondary to Retinal Vein Occlusion

Figure 1

(a) Branch retinal vein occlusion prior to therapy. Macular edema is present in the upper half of the macula. Corresponding color-coded thickness map (middle) and ETDRS mean retinal thickness values are shown (left). (b) 4 weeks after the loading phase (3 monthly injections of ranibizumab) the edema disappeared. Intraretinal exudates are still present. Central retinal thickness decreased from 331 to 241 μm. ETDRS visual acuity improved from 42 to 75 letters. (c) OCT findings in central retinal vein occlusion prior to therapy. A larger cyst can be appreciated in the foveal area. Central retinal thickness is 377 μm. (d) After the loading phase, central retinal thickness remained virtually unchanged. The cystic appearance of the retina is still present. ETDRS visual acuity improved from 45 to 48 letters.

(a)

(b)

(c)

(d)